- Acquired by Leap Therapeutics, Jan 2017
About
MacroCure Ltd is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers. The company's approach is to treat chronic and other hard-to-heal wounds by injecting the human body's own wound-healing and regenerative components directly into the wound. MacroCure's lead product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell's two phase 3 double-blind clinical trials target a broad indication for the treatment of diabetic foot ulcers and venous leg ulcers. MacroCure already has product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds. CureXcell has effectively treated more than 5,000 patients in commercial or clinical study settings in Israel. In 2017, MacroCure Ltd merged into Leap Therapeutics, Inc.
Headcount over time
Offices
Show all offices (1 more)
- USA
Q&A
- What is MacroCure's primary focus?
- MacroCure is a clinical-stage biopharmaceutical company focused on developing a therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers.
- What is MacroCure's lead product candidate?
- MacroCure's lead product candidate is CureXcell, a combination of living human white blood cells activated to facilitate healing and stimulate wound closure.
- What is the current status of MacroCure?
- MacroCure was acquired by Leap Therapeutics in January 2017 and is currently inactive.
- When was MacroCure founded?
- MacroCure was founded in January 2008.
- What was the total amount of funding raised by MacroCure?
- MacroCure raised a total of $102,000,000 USD.
- Which investors participated in MacroCure's April 2011 funding round?
- In April 2011, MacroCure raised $13,000,000 USD from investors including Viola Growth.
- Which investors participated in MacroCure's May 2012 funding round?
- In May 2012, MacroCure raised $35,000,000 USD from investors including Rainfall Ventures.
- What is the status of CureXcell's clinical trials?
- CureXcell has undergone two phase 3 double-blind clinical trials targeting diabetic foot ulcers and venous leg ulcers. It also has product approval as a medical device in Israel for chronic and hard-to-heal wounds.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | macrocure.com |
|---|---|
| linkedin.com/company/566839 | |
| YouTube | youtube.com/channel/UCcAHngMbpAgoQAGsa5A_zXQ |
Identifiers & details
| Legal name | Macrocure Ltd. |
|---|---|
| Former names | Leap Therapeutics |
| Founded | 2008-1 |
| Employees (exact) | 9 |
| Offices | USA |
| Status reason | Acquired (Inactive) by Leap Therapeutics on Jan 2017 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Leap Therapeutics 2017-01
Radar intelligence
Patents
| EPO | 6 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | macrocure.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514083765 |
|---|---|
| Status | מחוסלת מרצון — CLOSED |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-01-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2017 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | הסיבים 25 פתח תקווה |